Expand TBPH Menu
TBPH MENU

TBPH Latest Press Releases

-- November 20, 2025 --

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 PRNewswire 11:00 AM

-- November 19, 2025 --

Theravance Biopharma to Participate in Upcoming Investor Conferences PRNewswire 6:00 AM

-- November 10, 2025 --

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update PRNewswire 4:05 PM

-- October 29, 2025 --

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System PRNewswire 6:00 AM

-- October 27, 2025 --

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 PRNewswire 6:00 AM

-- October 16, 2025 --

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy Business Wire 8:05 AM

-- October 14, 2025 --

Theravance Biopharma to Present New Analyses Highlighting YUPELRI (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting PRNewswire 6:01 AM

-- September 2, 2025 --

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference PRNewswire 6:00 AM

-- August 25, 2025 --

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy PRNewswire 6:00 AM

-- August 12, 2025 --

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update PRNewswire 4:05 PM
Market Data Delayed 15 Minutes